(CercleFinance.com) – Sensorion announces that it has submitted a first Clinical Trial Authorization Application (CTA) for OTOF-GT to the MHRA, the UK Medicines Regulatory Agency, following extensive preclinical studies and production of a batch for the clinical trial.
This phase 1/2 trial (Audiogene) aims to evaluate the safety, tolerability and efficacy of intra-cochlear injection of OTOF-GT for the treatment of otoferlin gene-related hearing loss in patients up to 31 months old.
‘Hearing loss linked to otoferlin deficiency is responsible for nearly 8% of all cases of congenital hearing loss and approximately 20,000 people are affected in the United States and Europe’, underlines the biotechnology company.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
